Novel death receptor 5 antibody fusion protein and application thereof

Abstract

The invention relates to sDR5-Fc recombinant protein (ZJ501-5) with an amino acid sequence shown as SEQ ID NO: 2 and a gene shown as SEQ ID NO: 1 of the recombinant protein, and meanwhile, the invention discloses an application of the sDR5-Fc recombinant protein and the gene thereof in preparing medicines for treating immune liver diseases. In addition, bioactivity of the sDR5-Fc protein in vitro is 3 times higher than that of an sDR5-Fc product from R&D systems Company, the proportion of an N terminal splice variant is just about 1% and the sDR5-Fc protein is high in protein drug stability; and the sDR5-Fc protein provided by the invention, which can significantly improve a survival rate of mice having Con A induced acute autoimmune hepatitis, has a potential application value for treating autoimmune hepatitis in human being.

Description

technical field [0001] The invention relates to a recombinant protein, in particular to a novel death receptor 5 antibody fusion protein and its application. Background technique [0002] According to the statistics of the World Health Organization, the ratio of hepatitis patients to healthy people in the world is about 1 / 12 at this stage, that is, there may be one hepatitis patient in every 12 people, and this ratio is nearly ten times that of AIDS-infected people. Currently, there are close to 500 million patients with hepatitis B and C around the world, accounting for 1 / 12 of the global population. China is the country with the most hepatitis patients, and nearly 300,000 people die of liver-related diseases every year, such as liver cirrhosis and liver cancer. More than 500,000 people die of primary liver cancer every year in the world, and as many as 80% of primary liver cancers are caused by chronic hepatitis. Of the 400 million chronic hepatitis patients, 75% live in...

AI Technical Summary

Problems solved by technology

There is no company in the world that can produce sDR5-Fc protein on a large scale under GMP, only Sigma (Cat. No.: D9563, discontinued), Enzo lifesciences (Cat. No.: ALX-522-005), EXBIO antibodies (Cat. No.: EXB0007), Abcam (Cat. No.: AB83547) and R&D systems (Cat. No.: 631-T2) produce sDR5-Fc protein as a biochemical reagent. The DR5 gene sequences used in these five products are not the same, and the types of engineered cells used are also different. The protein-induced apoptosis ability is relatively poor, and the stability is poor, and there are different ratios of N-terminal splicing variants. These shortcomings will bring troubles to the later process development and quality standard formulation

Images